CELG Celgene Corporation
Bristol Myers Squibbs Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for...
Business Wire·2mo ago
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The company will participate in a fireside chat at the TD Cowen...
Business Wire·7mo ago
U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite...
Business Wire·7mo ago
Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (nivolumab) in combination with...
Business Wire·7mo ago
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb (NYSE:BMY) today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with...
Business Wire·7mo ago
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected...
Business Wire·7mo ago
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell...
Business Wire·7mo ago
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2024. We made good progress in 2024, which was capped by a fourth quarter of strong topline growth...
Business Wire·7mo ago
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab...
Business Wire·7mo ago
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene...
Business Wire·7mo ago